AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02739451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
Study NCT01315652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comorbidities treatment
Description:  Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up
Study NCT01315652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto-DAS
Description: Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits
Study NCT00511485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
Study NCT00511485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide
Study NCT03810235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Lidocaine Patch
Description: Transdermal Lidocaine Patch
Study NCT03810235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Hydrocolloid Placebo Patch
Description: hydrocolloid placebo patches
Study NCT01308632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolamide, irinotecan
Description: Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .
Study NCT02443272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel Loop Drainage
Description: Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
Study NCT02443272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
Study NCT02811575 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Description: Ileon and colon biopsy
Study NCT01016574 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Support Device for Prone radiation therapy (Giro-Couch)
Description: Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
Study NCT03845075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesofensine/Metoprolol
Description: During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
Study NCT03845075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
Study NCT03289299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
Study NCT03289299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase.
Study NCT03289299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
Study NCT03289299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
Study NCT01325571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsule
Description: oral
Study NCT01183715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or placebo
Description: PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
Study NCT01325571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04780243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling
Description: Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
Study NCT02699476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Social Therapy
Study NCT02699476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Computer Training
Study NCT02699476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Computer Training
Study NCT02699476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Trainer-Subject Sessions
Study NCT02798692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3
Study NCT02798692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3
Study NCT02798692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3
Study NCT02798692 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
Study NCT02699476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Trainer-Subject Sessions
Study NCT02699476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Games
Study NCT02949232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
Study NCT02949232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Dosing following the tapering scheme of the treatment of the treatment arm
Study NCT05269927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG
Description: resting state EEG
Study NCT05269927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DNA samples
Description: genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
Study NCT05269927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical data
Description: standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT).
Study NCT05269927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental data
Description: questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
Study NCT02713737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidified high-flow nasal cannula
Description: HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
Study NCT02713737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive ventilation
Description: TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
Study NCT01690923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal mask
Description: Nasal mask (Mirage Activa, Micro, FX)
Study NCT01690923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillows mask
Description: Nasal pillows mask (Swift FX)
Study NCT02377011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving cognitive behaviour therapy (PS CBT)
Study NCT00545571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
Study NCT03100864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: 12 weeks treatment
Study NCT02277197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)
Study NCT02277197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended.
Study NCT00639314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pylorus-preserving pancreaticoduodenectomy
Description: pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
Study NCT00639314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pylorus-resecting pancreaticoduodenectomy
Description: In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
Study NCT02115919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, Injection 200IU
Description: Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
Study NCT02115919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, injection 400IU
Description: Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
Study NCT02056002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Standard CPAP educational training
Study NCT02056002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Buddy System
Description: * Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy
Study NCT02056002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Educational Brochures
Study NCT02056002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Educational DVD videos mailed to participant
Study NCT00104637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)
Study NCT00104637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)
Study NCT01111422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
Study NCT00104637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg po tid
Study NCT00104637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 25 mg po tid
Study NCT05918393 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: functional communication training
Description: During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
Study NCT03757403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDD1609
Description: RDD1609 to be applied on the perianal area BID
Study NCT03757403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole 100 MG
Description: Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
Study NCT03571022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USE-MI System
Description: Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s).
Study NCT01447862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinavess (Vernakalant)
Description: 3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
Study NCT01447862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corvert (Ibutilide)
Description: Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
Study NCT02980705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1622 I dose
Description: Injection
Study NCT00307853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Study NCT00307853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Study NCT00307853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Study NCT03191123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic resection
Description: The aim of this intervention is to reach curative resection.
Study NCT02980705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose
Description: Injection
Study NCT02411708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Single two-hour infusion of SANGUINATE
Study NCT02411708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single two-hour infusion of placebo
Study NCT03191123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The aim of this intervention is one of the palliative treatment.
Study NCT05145608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine ER tablet 50mg
Description: In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
Study NCT01052623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
Description: 1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
Study NCT03486964 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
Study NCT05540730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait Analysis
Description: Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
Study NCT02579317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resonance Breathing
Description: Breathing is paced with a pre-installed iPhone app that includes a visual pacer.